Icagen, Inc. (ICGN) Q4 2010 Earnings Conference Call March 7, 2011 10:00 am ET Executives Richard Katz - Executive Vice President and Chief Financial Officer Kay Wagoner - Chief Executive Officer Analysts Christopher James - McNicoll, Lewis & Vlak Dominique Sémon - Merlin Nexus Chris Richard - Merlin Nexus Tore Steen - Anthem Funds PresentationOperator
Good day, ladies and gentlemen and welcome to the Fourth Quarter 2010 Icagen Incorporated Earnings Conference Call. My name is Dazzman [ph] and I’ll be your operator for today. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session. (Operator Instructions). I would now like to turn the conference over to your host to Dr. Richard Katz, Executive Vice President and Chief Financial Officer. Please proceed. Richard Katz - Executive Vice President and Chief Financial Officer: Thank you very much operator. Good morning everyone. Thanks for joining us today to discuss Icagen’s corporate research and clinical progress as well as our financial results for the fourth quarter and the yearend. With me here today is Kay Wagoner, our CEO and Greg Rigdon, our Head of New Product Development. Kay will start the call today with a general overview. I will then address the financial results and Greg will be available to answer questions as well. Before we begin, I would just like to read the following regarding any forward-looking statements that we may make today. Various remarks that we may make about the company's future expectations, plans and prospects constitute forward-looking statements for purposes of the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from these forward-looking statements as a result of various important factors, including those discussed in our most recent quarterly report as filed with the SEC.